Lipid Metabolism, Statins and Bleeding Risk During Anticoagulant Therapy: Emerging Pharmacological Insights.

Abstract

Lipid metabolism, coagulation, inflammation, and vascular integrity are closely interconnected biological systems. Although statins are primarily prescribed to reduce low-density lipoprotein cholesterol (LDL-C) and prevent atherosclerotic cardiovascular disease, increasing evidence indicates that these agents exert multiple pharmacological effects beyond lipid lowering, including modulation of endothelial function, platelet activation, tissue factor expression, thrombin generation, fibrinolysis, and thrombo-inflammation. These pleiotropic properties have generated growing interest in the potential role of statins as adjunctive modulators of thrombotic risk in patients receiving anticoagulant therapy. Venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism, is a major clinical setting in which anticoagulant treatment reduces recurrence and mortality but exposes patients to bleeding complications. Observational studies and registry-based analyses suggest that statin use may be associated with improved outcomes among anticoagulated patients with venous thromboembolism, particularly for all-cause mortality and early survival after pulmonary embolism. At the same time, emerging evidence suggests that very low LDL-C concentrations may be associated with increased bleeding risk during anticoagulation, raising important questions regarding the relationship between lipid availability, vascular stability, platelet function, and hemostatic balance. This review summarizes current pharmacological and clinical evidence linking lipid metabolism, statin therapy, anticoagulation, thrombosis, and bleeding. Particular attention is devoted to the mechanisms through which statins influence hemostatic pathways, the clinical evidence derived from venous thromboembolism cohorts, and the potential implications of LDL-C levels for personalized bleeding risk assessment. Future strategies that integrate lipid profiles, thrombotic and bleeding risk, and pharmacological modulation of coagulation may contribute to more individualized antithrombotic management.